Bruton's tyrosine kinase (Btk) is a non-receptor protein tyrosine kinase (PTK) that is expressed in all haemopoietic lineages except mature T cells and plasma cells. Despite the broad range of expression. mutations that inactivate this molecule affect primarily the development of the B-cell lineage. As a PTK, Btk could potentially be involved directly or indirectly in the processes that relate to the malignant transformation of all the cell lineages where this molecule is expressed. Previous studies have failed to demonstrate mutations in patients with B-cell origin acute lymphoblastic leukaemia (ALL). We have utilized a recently developed method that enables the rapid and convenient detection of mutations at the cDNA level, namely, the non-isotopic RNase cleavage assay (NIRCA) to analyse Btk sequences from 27 patients with different types of acute myeloid leukaemia (AML). The only alteration that we observed was a polymorphism at position 2031. This polymorphism has already been seen in previous studies. Furthermore, using the same methodology, we identified the Btk mutations in six XLA (X-linked agammaglobulinaemia) patients. Our results, although they do not exclude the involvement of Btk mutations in the development or progression of some type of AML, nevertheless suggest that such mutations do not constitute a major co-factor in the development of myeloid malignancies.

Ritis, K., Speletas, M., Tsironidou, V., Pardali, E., Kanariou, M., Moschese, V., et al. (1998). Absence of Bruton's tyrosine kinase (Btk) mutations in patients with acute myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 102(5), 1241-1248 [10.1046/j.1365-2141.1998.00914.x].

Absence of Bruton's tyrosine kinase (Btk) mutations in patients with acute myeloid leukaemia

MOSCHESE, VIVIANA;ROSSI, PAOLO;
1998-09

Abstract

Bruton's tyrosine kinase (Btk) is a non-receptor protein tyrosine kinase (PTK) that is expressed in all haemopoietic lineages except mature T cells and plasma cells. Despite the broad range of expression. mutations that inactivate this molecule affect primarily the development of the B-cell lineage. As a PTK, Btk could potentially be involved directly or indirectly in the processes that relate to the malignant transformation of all the cell lineages where this molecule is expressed. Previous studies have failed to demonstrate mutations in patients with B-cell origin acute lymphoblastic leukaemia (ALL). We have utilized a recently developed method that enables the rapid and convenient detection of mutations at the cDNA level, namely, the non-isotopic RNase cleavage assay (NIRCA) to analyse Btk sequences from 27 patients with different types of acute myeloid leukaemia (AML). The only alteration that we observed was a polymorphism at position 2031. This polymorphism has already been seen in previous studies. Furthermore, using the same methodology, we identified the Btk mutations in six XLA (X-linked agammaglobulinaemia) patients. Our results, although they do not exclude the involvement of Btk mutations in the development or progression of some type of AML, nevertheless suggest that such mutations do not constitute a major co-factor in the development of myeloid malignancies.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/38 - Pediatria Generale e Specialistica
eng
Con Impact Factor ISI
Acute Disease; Humans; Protein-Tyrosine Kinases; Aged; Child; Leukemia, Myeloid; DNA, Complementary; Adult; Middle Aged; Monocytes; Adolescent; Mutation; Female; Male
Ritis, K., Speletas, M., Tsironidou, V., Pardali, E., Kanariou, M., Moschese, V., et al. (1998). Absence of Bruton's tyrosine kinase (Btk) mutations in patients with acute myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 102(5), 1241-1248 [10.1046/j.1365-2141.1998.00914.x].
Ritis, K; Speletas, M; Tsironidou, V; Pardali, E; Kanariou, M; Moschese, V; Orlandi, P; Skordala, M; Rossi, P; Kartalis, G; Bourikas, G; Sideras, P
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Ritis_et_al-1998-British_Journal_of_Haematology.pdf

non disponibili

Licenza: Copyright dell'editore
Dimensione 462.91 kB
Formato Adobe PDF
462.91 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/66988
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 15
social impact